MedTrace Logo

A Phase IV, Prospective, Observational, Open Label, Single Centre Cohort Trial to be Conducted in Norway During One Year to Assess the Cumulative Pregnancy Rate in a New Series of In-vitro Fertilization (IVF) Treatment Cycles Following Three or More Previous IVF Treatment Cycles Without Live Birth

NCT01071148 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 166

Last updated 2014-05-05

No results posted yet for this study

Summary

The primary objective of this observational study is to assess the cumulative rate of ongoing pregnancy at 10 ±2 weeks after hCG administration in a new series of IVF-treatment cycles in a total of 176 subjects, who have undergone three or more previous IVF-treatment cycles without live birth. Secondary objectives include subgroup analysis on the effect of age on the likelihood of pregnancy at 10 ±2 weeks after hCG administration in a new series of IVF-treatment cycles in patients \< 35 years and ≥ 35 years, who have undergone three or more previous IVF-treatment cycles without live birth.

The information obtained from this trial will be helpful for subjects who are considering further IVF treatments and for IVF centres, as well as for the formulation of governmental policies regarding healthcare reimbursement in Norway.

Conditions

Sponsors & Collaborators

  • Merck Serono Norway

    collaborator INDUSTRY

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Viveka Åberg, MD · Merck Serono Norway

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01071148 on ClinicalTrials.gov